Adalimumab products — Prior authorization and medical necessity
Customize your policy alerts
Sign up for all harvard pilgrim health care policy alerts
Know when harvard pilgrim health care releases new policies or updates existing guidance.
Monitor payer policy activity
This guideline governs prior authorization and medical necessity criteria for coverage of adalimumab products (including multiple biosimilars and brands) for Harvard Pilgrim and affiliated commercial products; it applies to prescribers seeking coverage for members under the listed commercial and public plan products.
Added Starjemza as a prerequisite for Crohn's disease, plaque psoriasis, psoriatic arthritis, and ulcerative colitis to support the updated ustekinumab strategy.
Simlandi moved from non-preferred to preferred status and Humira moved from preferred to non-preferred status.
Members who initiated the requested medication by self-paying do not qualify as having an established clinical response and must be reviewed against initial approval criteria.
For hidradenitis suppurativa, plaque psoriasis and psoriatic arthritis, initial approval limited to 6 months with reauthorization in 12‑month intervals; for ankylosing spondylitis, Crohn's disease, polyarticular JIA, rheumatoid arthritis, ulcerative colitis and uveitis, authorizations provided in 12‑month intervals.
Coverage Criteria by Indication
Ankylosing Spondylitis — Initial and Reauthorization
Covered when ALL of the following are met
from chunks 8
from chunk 11
Crohn's Disease — Initial and Reauthorization
Covered when ALL of the following are met
from chunk 13
from chunk 14
Hidradenitis Suppurativa — Initial and Reauthorization
Covered when ALL of the following are met
from chunk 16
from chunk 17
Plaque Psoriasis — Initial and Reauthorization
Covered when ALL of the following are met
from chunk 18
from chunk 19
Initial Therapy (general) — Plaque Psoriasis initial
Covered when ALL of the following are met
Document drugs, dates, and durations of trials
Reauthorization (general) — Plaque Psoriasis reauth
Covered when ALL of the following are met
Initial Therapy (other indication block) — Polyarticular JIA initial
Covered when ALL of the following are met
Reauthorization (other indication block) — Polyarticular JIA reauth
Covered when ALL of the following are met
Initial Therapy (other indication block) — Psoriatic arthritis initial
Covered when ALL of the following are met
Reauthorization (other indication block) — Psoriatic arthritis reauth
Covered when ALL of the following are met
Initial Therapy (other indication block) — Rheumatoid Arthritis initial
Covered when ALL of the following are met
Reauthorization (other indication block) — Rheumatoid Arthritis reauth
Covered when ALL of the following are met
Initial Therapy (other indication block) — Ulcerative Colitis initial
Covered when ALL of the following are met
Reauthorization (other indication block) — Ulcerative Colitis reauth
Covered when ALL of the following are met
Initial Therapy (other indication block) — Uveitis initial
Covered when ALL of the following are met
Reauthorization (other indication block) — Uveitis reauth
Covered when ALL of the following are met
Humira (adalimumab) Additional — additional requirement for Humira products
Applies in addition to the coverage criteria for the requested indication
Applies in addition to indication-specific coverage criteria
Authorization duration and initial vs reauthorization — coverage duration and review rules
Coverage duration and review rules
Applies to authorization processing
Coverage will not be approved when the requested adalimumab product is being used concurrently with another biologic drug or with a targeted synthetic oral small molecule drug. Providers must document that the patient is not receiving the requested medication in combination with another biologic or targeted synthetic oral small molecule drug as a condition of authorization (see indication-specific criteria).
This prohibition applies to initial authorizations and reauthorizations across the listed indications and is included among the required documentation for prior authorization.
Documentation that a member is a social drinker does not constitute a medically acceptable contraindication to methotrexate therapy and therefore does not justify bypassing required prior therapy steps that include methotrexate where indicated.
When methotrexate is a required prior agent, providers should document a true contraindication or clinically significant adverse effect to methotrexate — simple documentation of social alcohol use alone is insufficient for authorization exceptions.
The plan considers documentation that a member is a social drinker to be inadequate as a medically acceptable contraindication or clinical inappropriateness for therapies (for example, methotrexate) that are required by the policy prior to biologic therapy.
Providers seeking an exception must demonstrate a documented contraindication or clinically significant adverse reaction to the agent in question; social alcohol use by itself will not meet that standard.
Members who began the requested medication through samples, free goods, similar offerings, or by self-paying directly do not qualify as having an established clinical response for purposes of reauthorization. Such members should be reviewed under the Initial Authorization Criteria.
Providers must submit documentation of how therapy was initiated and the duration of prior therapy; if initiation was via samples/free goods/self-pay, the member must meet initial prior-therapy and step requirements rather than being treated as an established responder.
Initial Authorization Requirements
Initial therapy requirements — overarching initial authorization requirements
Initial authorization criteria vary by indication but commonly require the following
Initial Authorization — per-indication initial authorization requirements
Initial authorization requirements per indication
Specific medications, age thresholds, and additional disease-specific requirements are specified in the indication-specific sections of the policy.
Initial Authorization Criteria (reference) — operational initial review guidance
Initial authorization review
Initial Authorization Criteria are defined in the indication-specific sections of the policy.
Reauthorization / Continuation Requirements
Reauthorization requirements by indication — demonstration of continued benefit per indication
Reauthorization requires demonstration of continued benefit and documentation per indication
Reauthorization — per-indication reauthorization requirements
Reauthorization requirements per indication
Medical charts should demonstrate improvement measures appropriate to the indication (e.g., BSA reduction for plaque psoriasis; joint counts for psoriatic arthritis; objective HS measures),
Reauthorization rules — reauthorization intervals
Reauthorization intervals
Continuation requires meeting the reauthorization documentation requirements described elsewhere in the policy
Therapeutic Step Requirements and Product Strategy
| Step | Requirement | Duration / Notes |
|---|---|---|
| 1 | ||
| Trial of the preferred adalimumab product Simlandi is required prior to coverage of other adalimumab products (document date and duration of a minimum three-month supply unless contraindicated) | ||
| Minimum 3 months trial of Simlandi; document drug, dates, and duration of trial. Applies across multiple indications per policy (see indication-specific criteria). |
| Step | Requirement | Applicable Indications / Notes |
|---|---|---|
| 1 | ||
| Documentation of history of failure to specified agents across therapeutic categories; typically requires failure to two medications from the listed classes (only one required if only one is available for a category). Document drug names, dates, and durations of trials. | ||
| {"text":"Applies to many indications (examples include plaque psoriasis, Crohn\'s disease, polyarticular JIA, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, hidradenitis suppurativa, uveitis). Specific class lists and agents are defined per indication in the policy.","status":""} |
| Step | Requirement | Affected Indications / Notes |
|---|---|---|
| 1 | ||
| Added Starjemza (preferred ustekinumab) as a prerequisite product for certain indications to align with the ustekinumab product strategy; providers must meet ustekinumab prerequisites where specified in the policy (nonbiologic prerequisites and disease severity requirements remain as indicated). | ||
| {"text":"Applied to Crohn\'s disease, plaque psoriasis, psoriatic arthritis, and ulcerative colitis per the June 9, 2026 revision; Yesintek and Starjemza are designated preferred ustekinumab products. See indication-specific sections for full prerequisite lists.","status":""} |
Provider Requirements, Documentation, and Denial Risks
Prior authorization required for adalimumab products
Prior authorization is required for all adalimumab products for the listed Harvard Pilgrim and Tufts commercial and specified public plan products; contact the plan using the fax numbers provided when submitting authorization requests.
Required prior authorization documentation and prescriber details
Submit documentation that includes the member's diagnosis, prescriber specialty, age, detailed prior therapy trials (drug names, dates, durations), and evidence the patient is not receiving the requested medication in combination with another biologic or targeted synthetic oral small molecule drug.
- Prescriber specialty (e.g., rheumatologist, dermatologist, gastroenterologist, ophthalmologist/ocular immunologist) as specified per indication
- Age per indication (examples: ≥18 years for plaque psoriasis; ≥6 years for Crohn's; ≥12 years for hidradenitis suppurativa; ≥2 years for polyarticular JIA)
- Document drug name, dates, and duration for all prior therapy trials including a minimum 3-month trial of Simlandi unless contraindicated
- Statement that the member is not receiving the requested medication with another biologic or targeted synthetic oral small molecule drug
Prior authorization duration and reauthorization intervals
Initial authorization durations vary by indication: hidradenitis suppurativa, plaque psoriasis, and psoriatic arthritis are initially authorized for 6 months; other listed indications (e.g., ankylosing spondylitis, Crohn's disease, polyarticular JIA, RA, ulcerative colitis, uveitis) are authorized in 12-month intervals. Members with less than the specified prior therapy duration or restarting therapy are reviewed under initial authorization criteria.
- Hidradenitis suppurativa, plaque psoriasis, psoriatic arthritis: initial approval = 6 months; reauthorization in 12-month intervals
- Ankylosing spondylitis, Crohn's disease, polyarticular JIA, rheumatoid arthritis, ulcerative colitis, uveitis: authorizations provided in 12-month intervals
- Members new to the plan or restarting therapy are reviewed under Initial Authorization Criteria
Step requirement: trial of preferred Simlandi (≥3 months)
For most indications, the member must have documented failure to specified classes/agents and must have trialed the preferred product Simlandi for a minimum three-month supply prior to approval of other adalimumab products, unless contraindicated.
- Document failure to required traditional/systemic agents and two medications from listed therapeutic categories (document drugs, dates, durations)
- Document a minimum 3-month trial of Simlandi unless contraindicated (note date and duration)
Therapeutic step: failures across classes and traditional agents
Therapeutic step requires documented failure to specified traditional systemic agents and failures across multiple therapeutic classes (typically two medications from the listed categories) in addition to the Simlandi trial.
- Fail at least one traditional/systemic agent (examples listed per indication: methotrexate, cyclosporine, acitretin, phototherapy, DMARDs)
- Fail two medications from listed therapeutic categories (interleukin antagonists, JAK inhibitors, TNF agents, PDE4 inhibitors, S1P modulators, etc.) — document drugs, dates, durations
- Fail a minimum 3-month supply of Simlandi unless contraindicated
Product-specific prerequisite: Starjemza added for some indications
For certain indications (Crohn's disease, plaque psoriasis, psoriatic arthritis, and ulcerative colitis) Starjemza (preferred ustekinumab product) has been added as a prerequisite in the ustekinumab product strategy; follow the nonbiologic and disease severity prerequisites noted elsewhere in the policy.
- Yesintek and Starjemza are referenced as preferred ustekinumab products in the policy revision
- Starjemza added as a prerequisite for coverage evaluation in specified indications
Provider submission: include diagnosis, age, specialty, and prior therapy details
When submitting an authorization request, providers must include diagnosis, patient age, prescriber specialty, and complete prior therapy details (drug names, dates, durations), including documentation of a Simlandi trial when required.
- Include prescriber specialty specified by indication (e.g., dermatologist for plaque psoriasis, gastroenterologist for Crohn's/ulcerative colitis)
- Provide precise dates and durations for prior therapy trials and Simlandi trial (if applicable)
Required documentation for initial authorization and reauthorization
Required documentation for initial requests and reauthorization includes the diagnosis, prescriber specialty, age, prior therapy trials with drug names/dates/durations, and for reauthorization, medical chart evidence of clinical improvement or stabilization compared to baseline as specified by indication.
- Initial requests: document diagnosis, age, prescriber specialty, prior therapy trials (drug, date, duration)
- Reauthorization: submit medical charts showing beneficial clinical response (e.g., reduction in BSA for plaque psoriasis, objective measures for hidradenitis suppurativa, improvement in joint counts for psoriatic arthritis)
- Always document that the patient is not receiving concomitant biologic or targeted synthetic oral small molecule therapy
Document prior initiation and duration to determine review pathway
Document whether the member previously initiated the requested medication and the duration of prior therapy to determine if the case should be reviewed under initial authorization criteria or continuation/reauthorization rules.
- If member initiated therapy via plan-covered fills and has met the duration thresholds, consider reauthorization criteria
- If member has received less than the required duration or is restarting therapy, review under Initial Authorization Criteria
Denial risk if required documentation is missing
Coverage may be denied if required documentation is missing, including the diagnosis, specialist prescriber, documentation of prior therapy trials (including trial of Simlandi where required), age requirements, or evidence the patient is not receiving concomitant biologic or targeted synthetic oral small molecule therapy.
- Missing dates/durations for prior therapy trials or absence of a documented Simlandi trial (when required) risks denial
- Lack of prescriber specialty documentation or age not meeting indication thresholds can lead to denial
Established response not recognized for samples/free goods/self-pay initiation
Members who initiated the requested medication using samples, free goods, or by self-paying directly do not qualify as having an established clinical response and should be reviewed against initial authorization criteria; lack of qualifying established response may result in denial.
- If therapy was started via samples, free goods, or self-pay, submit full initial authorization documentation — these starts are not accepted as established response
- Administrative update clarifies self-pay initiation does not confer established status
Coding and Key Clinical Values
| No codes listed |
| No codes listed |
Preferred Product and Biosimilar Strategy
Simlandi preferred; 3-month trial required
Simlandi is the preferred adalimumab product; a minimum three-month trial of Simlandi is required (unless contraindicated) prior to approval of other adalimumab products.
- Document the date and duration of at least a 3-month Simlandi trial unless contraindicated
Humira-specific requirement: document failure to listed biosimilars/brands
For Humira (adalimumab) products, documentation of failure to the listed adalimumab biosimilars and brands is required in addition to meeting the indication-specific criteria.
- Document failure to the listed biosimilars/brands (Adalimumab-aacf, -aaty, -adaz, -adbm, -fkjp, -ryvk, Abrilada, Amjevita, Cyltezo, Hadlima, Hulio, Hyrimoz, Idacio, Yuflyma, Yusimry) with dates and durations
Formulary status changes: Simlandi preferred; Humira non-preferred
Formulary status changed: Simlandi moved from non-preferred to preferred status and Humira moved from preferred to non-preferred status.
Key Definitions and Product Lists
Background
Adalimumab is a tumor necrosis factor (TNF) blocker approved for multiple immune-mediated inflammatory conditions listed in this guideline. The policy covers branded adalimumab and numerous biosimilar formulations.
Multiple adalimumab biosimilars and brand products are included in the guideline’s scope (for example, Simlandi and Humira among others), and the policy specifies a preferred biosimilar strategy in which a minimum three-month trial of the preferred product Simlandi is required prior to coverage of other adalimumab products unless contraindicated.
The guideline also records recent formulary and strategy updates, including movement of Simlandi to preferred status and Humira to non-preferred status, and the addition of product-specific prerequisites in support of the ustekinumab strategy (e.g., Starjemza).
Policy Revision History
Added Starjemza as a prerequisite for Crohn's disease, plaque psoriasis, psoriatic arthritis, and ulcerative colitis to support the updated ustekinumab strategy; Yesintek and Starjemza designated as preferred ustekinumab products.
Simlandi moved from non-preferred to preferred status and Humira moved from preferred to non-preferred status (effective 2026-03-01).
Updated provider requirements to prevent duplicative targeted immunomodulator therapy and specified initial approval durations and reauthorization intervals by indication (6 months initial for hidradenitis suppurativa, plaque psoriasis, psoriatic arthritis; 12 months initial for other listed indications).
Reviewed by the Pharmacy & Therapeutics Committee (effective 2025-09-01).
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.